Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Ouvrir la porte J
  • JournalSeek de génamique
  • RechercheBible
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • ICMJE
Partager cette page

Abstrait

Pancreatic Squamous Cell Carcinoma: A Case Report and Review of the Literature

Fadwa Oudad, Nezha Tawfiq, Zineb Bouchbika, Nadia Benchakroun, Hassan Jouhadi, Souha Sahraoui, Abdellatif Benider

Background: Pancreatic squamous cell carcinoma is an exceptional disease. The pancreas is completely devoid of squamous cells, the development of squamous cell carcinoma at its level is controversial and of unknown origin. Squamous metaplasia of ductal cells has been observed in inflammatory episodes of pancreatic tissue. However, transformation to a squamous cell carcinoma remains exceptional. It is a very aggressive disease, most often locally advanced or metastatic at the time of diagnosis, and not very sensitive to the treatments offered.

Case Presentation: We describe here a case of a 64-year-old woman treated for a locally advanced pancreatic squamous cell carcinoma revealed by just diffuse abdominal pain. The diagnosis was confirmed by a peritoneal biopsy. She underwent palliative chemotherapy according to the protocol Capecitabine-Cisplatin, but the outcome was pejorative since she showed after 4 cures an enormous progression, preventing her from trying out another drug.

Conclusion: Due to the rarity of primary breast neuroendocrine tumors, no standard therapy exists.

We want to show through this case the pejorative prognosis of this rare tumor, and to motivate further prospective works in order to finally establish a better protocol to enhance our patients’ outcomes.